WallStreetZenWallStreetZen

NASDAQ: GTHX
G1 Therapeutics Inc Stock

$4.53-0.15 (-3.21%)
Updated May 17, 2024
GTHX Price
$4.53
Fair Value Price
N/A
Market Cap
$236.83M
52 Week Low
$1.08
52 Week High
$6.14
P/E
-7.68x
P/B
8.54x
P/S
2.68x
PEG
N/A
Dividend Yield
N/A
Revenue
$84.04M
Earnings
-$30.59M
Gross Margin
91.9%
Operating Margin
-22.07%
Profit Margin
-36.4%
Debt to Equity
2.68
Operating Cash Flow
-$18M
Beta
1.51
Next Earnings
Jun 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A

GTHX Overview

G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, a (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer; Phase III clinical trial for the treatment of first line triple negative breast cancer; Phase II clinical trial for patients with first line bladder cancer; Phase II clinical trial for patients with combination with the antibody-drug conjugate; and Phase II clinical trial for the treatment of neoadjuvant breast cancer. In addition, the company develops lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer. The company has a license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.

Zen Score

Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how GTHX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

GTHX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
GTHX is poor value based on its book value relative to its share price (8.54x), compared to the US Biotechnology industry average (6.01x)
P/B vs Industry Valuation
GTHX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more GTHX due diligence checks available for Premium users.

Be the first to know about important GTHX news, forecast changes, insider trades & much more!

GTHX News

Valuation

GTHX fair value

Fair Value of GTHX stock based on Discounted Cash Flow (DCF)
Price
$4.53
Fair Value
-$0.02
Undervalued by
25,917.77%
GTHX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

GTHX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-7.68x
Industry
8.47x
Market
30.97x

GTHX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
8.54x
Industry
6.01x
GTHX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

GTHX's financial health

Profit margin

Revenue
$14.5M
Net Income
-$10.2M
Profit Margin
-70.6%
GTHX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
GTHX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$102.0M
Liabilities
$74.3M
Debt to equity
2.68
GTHX's short-term assets ($95.84M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GTHX's short-term assets ($95.84M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GTHX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
GTHX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$8.9M
Investing
$5.3M
Financing
-$8.7M
GTHX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

GTHX vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
GTHX$236.83M-3.21%-7.68x8.54x
ALDX$234.69M-3.42%-7.75x2.07x
FHTX$234.65M-5.16%-2.50x-2.41x
ELYM$240.00M+0.86%-15.57x2.26x
AKBA$241.04M+0.88%-5.00x-8.84x

G1 Therapeutics Stock FAQ

What is G1 Therapeutics's quote symbol?

(NASDAQ: GTHX) G1 Therapeutics trades on the NASDAQ under the ticker symbol GTHX. G1 Therapeutics stock quotes can also be displayed as NASDAQ: GTHX.

If you're new to stock investing, here's how to buy G1 Therapeutics stock.

What is the 52 week high and low for G1 Therapeutics (NASDAQ: GTHX)?

(NASDAQ: GTHX) G1 Therapeutics's 52-week high was $6.14, and its 52-week low was $1.08. It is currently -26.22% from its 52-week high and 319.44% from its 52-week low.

How much is G1 Therapeutics stock worth today?

(NASDAQ: GTHX) G1 Therapeutics currently has 52,281,391 outstanding shares. With G1 Therapeutics stock trading at $4.53 per share, the total value of G1 Therapeutics stock (market capitalization) is $236.83M.

G1 Therapeutics stock was originally listed at a price of $15.00 in May 17, 2017. If you had invested in G1 Therapeutics stock at $15.00, your return over the last 7 years would have been -69.8%, for an annualized return of -15.72% (not including any dividends or dividend reinvestments).

How much is G1 Therapeutics's stock price per share?

(NASDAQ: GTHX) G1 Therapeutics stock price per share is $4.53 today (as of May 17, 2024).

What is G1 Therapeutics's Market Cap?

(NASDAQ: GTHX) G1 Therapeutics's market cap is $236.83M, as of May 19, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

G1 Therapeutics's market cap is calculated by multiplying GTHX's current stock price of $4.53 by GTHX's total outstanding shares of 52,281,391.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.